Probuphine is owned by Titan Pharms.
Probuphine contains Buprenorphine Hydrochloride.
Probuphine has a total of 1 drug patent out of which 0 drug patents have expired.
Probuphine was authorised for market use on 26 May, 2016.
Probuphine is available in implant;implantation dosage forms.
Probuphine can be used as for opioid dependence.
The generics of Probuphine are possible to be released after 25 April, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7736665||TITAN PHARMS||Implantable polymeric device for sustained release of buprenorphine|| |
(1 year, 2 months from now)
Market Authorisation Date: 26 May, 2016
Treatment: For opioid dependence
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic